Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinprezo in Platinum-Resistant Ovarian Cancer
NCT00408603Phase 2Completed
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Dec 2006
- Primary completion
- Jun 2010
- Countries
- 2
01
Overview
Phase 2, open-label trial of vosaroxin in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by Sunesis Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate at Cycle 6. Started Dec 2006; status: completed.
02
Drugs
vosaroxin
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00408603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408603.